Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis — Competitive Intelligence Brief

Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis (Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

marketed Vaccine The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins. Immunology Biologic

Target snapshot

Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis (Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis) — Sanofi Pasteur, a Sanofi Company. The Tdap vaccine works by introducing inactivated toxins from the bacteria that cause tetanus, diphtheria, and pertussis, stimulating the immune system to produce antibodies against these pathogens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis TARGET	Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis	Sanofi Pasteur, a Sanofi Company	marketed	Vaccine	The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins.
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
fIPV (0.1 mL) ID	fIPV (0.1 mL) ID	Centers for Disease Control and Prevention	marketed	vaccine	poliovirus types 1, 2, and 3 antigens
MenACWY-TT	MenACWY-TT	Pfizer	marketed	Meningococcal conjugate vaccine
Rotavirus vaccine	Rotavirus vaccine	PATH	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
3. Pfizer · 6 drugs in this class
4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
5. Henogen · 3 drugs in this class
6. Pfizer Inc. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
9. BioNTech · 2 drugs in this class
10. Merck Sharp & Dohme LLC · 2 drugs in this class